Fibrinogen and antithrombin in hematological patients with neutropenic fever

Central European Journal of Medicine

Volumn 5, Issue 4, 2010, Pages 520-526

  Matinlauri, Irma ^a,b   Juutilainen, Auni ^c   Hämäläinen, Sari ^c   Koivula, Irma ^c   Kuittinen, Taru ^c   Jantunen, Esa ^c  

^a UNIVERSITY OF EASTERN FINLAND   (Finland)

^b TURKU UNIVERSITY HOSPITAL   (Finland)

^c KUOPIO UNIVERSITY HOSPITAL   (Finland)

Author keywords

Antithrombin; Fibrinogen; Hematological patients; Neutropenic fever; Severe sepsis

Indexed keywords

ANTITHROMBIN; C REACTIVE PROTEIN; CARMUSTINE; CYCLOPHOSPHAMIDE; CYTARABINE; ETOPOSIDE; FIBRINOGEN; IDARUBICIN; MELPHALAN; MITOXANTRONE; TIOGUANINE;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; AMYLOIDOSIS; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; BLOOD CULTURE; BLOOD SAMPLING; CANCER CHEMOTHERAPY; CHRONIC LYMPHATIC LEUKEMIA; CONTROLLED STUDY; DISEASE SEVERITY; DRUG MEGADOSE; FEBRILE NEUTROPENIA; FEMALE; FEVER; FIBRINOGEN BLOOD LEVEL; HEMATOLOGIC MALIGNANCY; HODGKIN DISEASE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIPLE MYELOMA; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SEPSIS;

EID: 77955984634     PISSN: 18951058     EISSN: 16443640     Source Type: Journal    
DOI: 10.2478/s11536-010-0012-y     Document Type: Article

References (18)

1. Hämäläinen S, Kuittinen T, Matinlauri I, Nousiainen T, Koivula I, Jantunen E, Neutropenic fever and severe sepsis in adult acute myeloid leukemia (AML) patients receiving intensive chemotherapy: causes and consequences, Leuk Lymphoma, 2008, 49, 495-501
2. Hämäläinen S, Kuittinen T, Matinlauri I, Nousiainen T, Koivula I, Jantunen E, Severe sepsis in autologous stem cell transplant recipients: microbiological aetiology, risk factors and outcome, Scand J Infect Dis, 2009, 41, 14-20
3. Krüger W, Rüssmann B, Kröger N, Salomon C, Ekopf N, Elsner H-A, et al., Early infections in patients undergoing bone marrow or blood stem cell transplantation - a 7 year single centre investigation of 409 cases, Bone Marrow Transplant, 1999, 23, 589-597
4. Jantunen E, Itälä M, Lehtinen T, Kuittinen O, Koivunen E, Leppä S, et al., Early treatment-related mortality in adult autologous stem cell transplant recipients: a nation-wide survey of 1482 transplanted patients, Eur J Haematol, 2006, 76, 245-250
5. Persson L, Engervall P, Magnuson A, Vikerfors T, Söderquist B, Hansson L-O, et al., Use of inflammatory markers for early detection of bacteraemia in patients with febrile neutropenia, Scand J Infect Dis, 2004, 36, 365-371
6. Esmon CT, The interactions between inflammation and coagulation, Br J Haematol, 2005, 131, 417-430
7. Levi M, Keller TT, Van Gorp E, Ten Cate H, Infection and inflammation and the coagulation system, Cardiovasc Res, 2003, 60, 26-39
8. Schouten M, Wiersinga J, Levi M, Van der Poll T, Inflammation, endothelium, and coagulation in sepsis, J Leukoc Biol, 2008, 83, 536-545
9. Mesters RM, Mannucci PM, Coppola R, Keller T, Ostermann H, Kienast, J, Factor VIIa and antithrombin III activity during severe sepsis and septic shock in neutropenic patients, Blood, 1996, 88, 881-886
10. Zeerleder S, Hack CE, Wuillemin WA, Disseminated intravascular coagulation in sepsis, Chest, 2005, 128, 2864-2875
11. Fourier F, Chopin C, Huart J-J, Runge I, Caron C, Goudemand J, Double-blind, placebo-controlled trial of antithrombin III concentrates in septic shock with disseminated intravascular coagulation, Chest, 1993, 104, 882-888
12. Hunault-Berger M, Chevallier P, Delain M, BulaboisC-E, Bologna S, Bernard M, et al., Changes in antithrombin and fibrinogen levels during induction chemotherapy with L-asparaginase in adult patients with acute lymphoblastic leukemia or lymphoblastic lymphoma. Use of supportive coagulation therapy and clinical outcome: the CAPELAL study, Haematologica, 2008, 93, 1488-1494
13. Hughes WT, Armstrong D, Bodey GP, Bow EJ, Brown AE, Calandra T, et al., 2002 guidelines for the use of antimicrobial agents in neutropenic patients with cancer, Clin Infect Dis, 2002, 34, 730-751
14. Bone RC, Balk RA, Cerra FB, Dellinger RP, Fein AM, Knaus WA, et al., Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM Consensus Conference Committee. American College of Chest Physicians/Society of Critical Care Medicine., Chest, 1992, 101, 1644-1655
15. Levy MM, Fink MP, Marshall JC, Abraham E, Angus D, Cook D, et al., 2001 SCCM/ESICM/ACCP/ATS/ SIS International Sepsis Definitions Conference, Crit Care Med, 2003, 31, 1250-1256
16. Delves PJ, Roitt IM, The immune system, N Engl J Med, 2000, 343, 37-49
17. Gonano C, Sitzwohl C, Meitner E, Weinstabl C, Kettner SC, Four-day antithrombin therapy does not seem to attenuate hypercoagulability in patients suffering from sepsis, Crit Care, 2006, 10, 160-165
18. Falanga A, Zacharski L, Deep vein thrombosis in cancer: the scale of the problem and approaches to management, Ann Oncol, 2005, 16, 696-7701